ENUMERAL BIOMEDICAL HOLDINGS, INC. (ENUM) financial statements (2021 and earlier)
Company profile
| Business Address |
200 CAMBRIDGEPARK DRIVE, SUITE 2000 CAMBRIDGE, MA 02140 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2016 | 12/31/2015 | 12/31/2014 | 10/31/2013 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 3,162 | 3,596 | 13,470 | 18 | ||
| Cash and cash equivalents | 3,162 | 3,596 | 10,460 | 18 | ||
| Short-term investments | 3,010 | |||||
| Receivables | 189 | 306 | 284 | |||
| Other current assets | 6 | |||||
| Other undisclosed current assets | 47 | 280 | 202 | |||
| Total current assets: | 3,399 | 4,183 | 13,957 | 24 | ||
| Noncurrent Assets | ||||||
| Property, plant and equipment | 902 | 1,511 | 1,007 | |||
| Restricted cash and investments | 535 | 535 | 562 | |||
| Other noncurrent assets | 112 | 115 | 8 | |||
| Total noncurrent assets: | 1,548 | 2,161 | 1,578 | |||
| TOTAL ASSETS: | 4,947 | 6,344 | 15,535 | 24 | ||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 309 | 344 | 614 | 2 | ||
| Accounts payable | 309 | 344 | 614 | 2 | ||
| Debt | 252 | 240 | ||||
| Derivative instruments and hedges, liabilities | 2,138 | 16,119 | ||||
| Due to related parties | 78 | |||||
| Deferred revenue and credits | 15 | 131 | 236 | |||
| Other undisclosed current liabilities | 386 | 714 | 71 | |||
| Total current liabilities: | 961 | 3,567 | 17,117 | 2 | ||
| Noncurrent Liabilities | ||||||
| Long-term debt and lease obligation | 15 | 266 | ||||
| Capital lease obligations | 15 | 266 | ||||
| Liabilities, other than long-term debt | 63 | 37 | 101 | 13 | ||
| Deferred revenue and credits | 63 | 37 | 101 | |||
| Due to related parties | 13 | |||||
| Total noncurrent liabilities: | 78 | 303 | 101 | 13 | ||
| Total liabilities: | 1,039 | 3,871 | 17,219 | 15 | ||
| Stockholders' equity | ||||||
| Stockholders' equity attributable to parent | 3,908 | 2,473 | (1,684) | 9 | ||
| Common stock | 128 | 52 | 52 | 6 | ||
| Additional paid in capital | 30,045 | 16,822 | 15,965 | 23 | ||
| Accumulated other comprehensive loss | (10) | |||||
| Accumulated deficit | (26,265) | (14,401) | (17,691) | (20) | ||
| Total stockholders' equity: | 3,908 | 2,473 | (1,684) | 9 | ||
| TOTAL LIABILITIES AND EQUITY: | 4,947 | 6,344 | 15,535 | 24 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2016 | 12/31/2015 | 12/31/2014 | 10/31/2013 | ||
|---|---|---|---|---|---|
| Gross profit: | 2,453 | 1,489 | 164 | ||
| Operating expenses | (9,426) | (12,190) | (6,595) | (19) | |
| Operating loss: | (6,973) | (10,700) | (6,431) | (19) | |
| Nonoperating income (expense) | (4,883) | 13,990 | (1,749) | ||
| Other nonoperating expense | (1,691) | ||||
| Interest and debt expense | (4,266) | 10 | (242) | ||
| Income (loss) from continuing operations before equity method investments, income taxes: | (16,122) | 3,300 | (8,422) | (19) | |
| Other undisclosed income (loss) from continuing operations before income taxes | 4,266 | (10) | 242 | ||
| Net income (loss) available to common stockholders, diluted: | (11,856) | 3,290 | (8,179) | (19) | |
Comprehensive Income ($ in thousands)
| 12/31/2016 | 12/31/2015 | 12/31/2014 | 10/31/2013 | ||
|---|---|---|---|---|---|
| Net income (loss): | (11,856) | 3,290 | (8,179) | (19) | |
| Other comprehensive loss | (3,300) | ||||
| Comprehensive loss: | (11,856) | (10) | (8,179) | (19) | |
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (10) | ||||
| Comprehensive loss, net of tax, attributable to parent: | (11,856) | (10) | (8,189) | (19) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.